Nothing Special   »   [go: up one dir, main page]

Kamijo et al., 2006 - Google Patents

Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody

Kamijo et al., 2006

Document ID
3848843189148073476
Author
Kamijo S
Nakajima A
Ikeda K
Aoki K
Ohya K
Akiba H
Yagita H
Okumura K
Publication year
Publication venue
Biochemical and biophysical research communications

External Links

Snippet

Receptor activator of NF-κB (RANK) and its ligand (RANKL) are pivotal regulators of osteoclast differentiation. RANK and RANKL also mediate T cell/dendritic cell (DC) interaction. Previous study has shown that RANK/RANKL interaction induces prolonged DC …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Kamijo et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody
Yu et al. Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells
Weitzmann The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis
Clowes et al. The role of the immune system in the pathophysiology of osteoporosis
Li et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo
Schett et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor–transgenic mice
Pacifici The immune system and bone
KR100717901B1 (en) Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
Pacifici Estrogen deficiency, T cells and bone loss
Eddleston et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis
TWI636994B (en) Dkk1 antibodies and methods of use
Carpentier et al. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice.
US20160250224A1 (en) Orexin-control of bone formation and loss
IL258029B (en) Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
Holoshitz et al. An HLA-DRB1–coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity
Shukla et al. Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions
Fouque-Aubert et al. Influence of RANKL inhibition on immune system in the treatment of bone diseases
JP2013216677A (en) Method for treating autoimmune disease
US20190092848A1 (en) Methods of treating bone diseases, disorders and/or injuries and reagents therefor
Sapra et al. “Immunoporosis”: immunology of osteoporosis
Ko et al. A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
Ahmad et al. Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions
Zheng et al. Blockade of substance P receptor attenuates osteoporotic pain, but not bone loss, in ovariectomized mice
JP2010285448A (en) Method for modulating bone development
Wang et al. Characterization and functional study of five novel monoclonal antibodies against human OX40L highlight reverse signalling: enhancement of IgG production of B cells and promotion of maturation of DCs